Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Wright, P. Articles by Breier, A. Search for Related Content PubMed Citation Articles by Wright, P. Articles by Breier, A. Schizophrenia Spectrum Disorders Other Neuroleptics

Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia

OBJECTIVE: The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia. METHOD: Hospitalized patients with schizophrenia received one to three injections of intramuscular olanzapine, 10 mg, intramuscular haloperidol, 7.5 mg, or intramuscular placebo over a 24-hour period. Agitation was measured with the excited component of the Positive and Negative Syndrome Scale and two additional scales. RESULTS: According to scores on the excited component of the Positive and Negative Syndrome Scale, both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2 and 24 hours following the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30, and 45 minutes following the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia, compared with 7% of those who were treated with intramuscular haloperidol. No significant QT_c interval changes were observed in any patients. CONCLUSIONS: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.

This article has been cited by other articles:

				C. DAMSA, E. ADAM, C. LAZIGNAC, A. MIHAI, F. DE GREGORIO, J. LEJEUNE, S. MARIS, E. CLIVAZ, and M. H. ALLEN A Naturalistic Study of Consecutive Agitated Emergency Department Patients Treated With Intramuscular Olanzapine Prior to Consent Am J Psychiatry, April 1, 2008; 165(4): 535 - 536. [Full Text] [PDF]

				D. R. Spiegel, D. P. Casella, D. M. Callender, and N. Dhadwal Treatment of Akinetic Mutism with Intramuscular Olanzapine: A Case Series J Neuropsychiatry Clin Neurosci, February 1, 2008; 20(1): 93 - 95. [Abstract] [Full Text] [PDF]

				G. Phillips McEnany Psychopharmacologic Strategies and Associated Challenges in the Long-Term Treatment of Schizophrenia Journal of the American Psychiatric Nurses Association, November 1, 2007; 13(5_suppl): S6 - S15. [Abstract] [PDF]

				N. S Raveendran, P. Tharyan, J. Alexander, C. E. Adams, and TREC-India II Collaborative Group Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine BMJ, October 27, 2007; 335(7625): 865 - 865. [Abstract] [Full Text] [PDF]

				R. Hodgson, C. Bushe, and R. Hunter Measurement of long-term outcomes in observational and randomised controlled trials The British Journal of Psychiatry, August 1, 2007; 191(50): s78 - s84. [Abstract] [Full Text] [PDF]

				S. Kapur, T. Arenovich, O. Agid, R. Zipursky, S. Lindborg, and B. Jones Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment Am J Psychiatry, May 1, 2005; 162(5): 939 - 946. [Abstract] [Full Text] [PDF]

				K. J Tulloch and P. J Zed Intramuscular Olanzapine in the Management of Acute Agitation Ann. Pharmacother., December 1, 2004; 38(12): 2128 - 2135. [Abstract] [Full Text] [PDF]

				C. Bushe and B. Leonard Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data The British Journal of Psychiatry, April 1, 2004; 184(47): s87 - s93. [Abstract] [Full Text] [PDF]

				O. Agid, S. Kapur, T. Arenovich, and R. B. Zipursky Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected Arch Gen Psychiatry, December 1, 2003; 60(12): 1228 - 1235. [Abstract] [Full Text] [PDF]

				G. Reid and M. Hughson Droperidol dropped; consultants not consulted: A survey of the practice of rapid tranquillisation by consultant psychiatrists in the west of Scotland Psychiatr. Bull., August 1, 2003; 27(8): 301 - 304. [Abstract] [Full Text] [PDF]

				A Yildiz, G S Sachs, and A Turgay Pharmacological management of agitation in emergency settings Emerg. Med. J., July 1, 2003; 20(4): 339 - 346. [Abstract] [Full Text] [PDF]

				D. G. Daniel Recent Developments in Pharmacotherapy for the Acutely Psychotic Patient Journal of the American Psychiatric Nurses Association, December 1, 2002; 8(6_suppl): S40 - S47. [PDF]

				R. H. McALLISTER-WILLIAMS and I. N. FERRIER Rapid tranquillisation: time for a reappraisal of options for parenteral therapy The British Journal of Psychiatry, June 1, 2002; 180(6): 485 - 489. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us